US4472383A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Peptide derivatives, their production and use
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1983-04-18
•
Granted: 1984-09-18
•
Expires: 2003-04-18
Abstract
Abstract Novel peptide derivatives, inclusive of salts thereof, of the formula <IMAGE> wherein A represents monocyclic or bicyclic hydrocarbon group, R1 and R3 are independently hydrogen, C1-4 alkyl or phenyl-C1-4 alkyl, and R2, R4 and R5 are independently hydrogen or C1-4 alkyl, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.
Inventors
- 👤 Yoshikazu Oka
- 👤 Kohei Nishikawa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 05:39
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/02; C07K5/022; A; A61; A61P; A61P43/00; A61P9/00; A61P9/12
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
66 words
A compound of the formula: ##STR11## wherein A is a C 3-8 cycloalkyl, C 5-8 cycloalkenyl, cyclohexadienyl, phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, bicyclo[4,4,0]decyl, bicyclo[4,3,0]nonyl, bicyclo[3,3,0]octyl, bicyclo[2,2,1]heptyl or bicyclo[2,2,2]octyl group, R 1 and R 3 are independently hydrogen, C 1-4 alkyl or phenyl-C 1-4 alkyl, and R 2 , R 4 and R 5 are independently hydrogen or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
66 words
A compound of the formula: ##STR11## wherein A is a C 3-8 cycloalkyl, C 5-8 cycloalkenyl, cyclohexadienyl, phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, bicyclo[4,4,0]decyl, bicyclo[4,3,0]nonyl, bicyclo[3,3,0]octyl, bicyclo[2,2,1]heptyl or bicyclo[2,2,2]octyl group, R 1 and R 3 are independently hydrogen, C 1-4 alkyl or phenyl-C 1-4 alkyl, and R 2 , R 4 and R 5 are independently hydrogen or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
14 words
A compound according to claim 1, wherein A is C 3-8 cycloalkyl or indanyl.
Claim 4
Dependent Claim
13 words
A compound according to claim 1, wherein R 1 is phenyl-C 1-4 alkyl.
Claim 5
Dependent Claim
13 words
A compound according to claim 1, wherein R 2 is C 1-4 alkyl.
Claim 6
Dependent Claim
13 words
A compound according to claim 1, wherein R 3 is phenyl-C 1-4 alkyl.
Claim 7
Dependent Claim
11 words
A compound according to claim 1, wherein R 4 is hydrogen.
Claim 8
Dependent Claim
13 words
A compound according to claim 1, wherein R 5 is C 1-4 alkyl.
Claim 9
Dependent Claim
23 words
A compound according to claim 1, wherein A is 2-indanyl, R 2 is methyl, R 3 is β-phenethyl and R 5 is ethyl.
Claim 10
Dependent Claim
9 words
The compound according to claim 1, which is N-[1-butoxycarbonyl-3-phenylpropyl]-L-alanyl-N-cyclopentylglycyl-L-phenylalanine.
Claim 11
Dependent Claim
9 words
The compound according to claim 1, which is N-[1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N-(2-indanyl)glycyl-L-phenylalanine.
Claim 12
Dependent Claim
9 words
The compound according to claim 1, which is N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N-(2-indanyl)glycyl-L-phenylalanine.
Claim 13
Dependent Claim
96 words
A pharmaceutical composition suitable for prevention or treatment of hypertension which comprises, as an active ingredient, an effective antihypertensive amount of a compound of the formula: ##STR12## wherein A is a C 3-8 cycloalkyl, C 5-8 cycloalkenyl, cyclohexadienyl, phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, bicyclo[4,4,0]decyl, bicyclo[4,3,0]nonyl, bicyclo[3,3,0]octyl, bicyclo[2,2,1]heptyl or bicyclo[2,2,2]octyl group, R 1 and R 3 are independently hydrogen, C 1-4 alkyl or phenyl-C 1-4 alkyl, and R 2 , R 4 and R 5 are independently hydrogen or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent therefor.
Claim 14
Dependent Claim
96 words
A pharmaceutical composition suitable for prevention or treatment of hypertension which comprises, as an active ingredient, an effective antihypertensive amount of a compound of the formula: ##STR12## wherein A is a C 3-8 cycloalkyl, C 5-8 cycloalkenyl, cyclohexadienyl, phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, bicyclo[4,4,0]decyl, bicyclo[4,3,0]nonyl, bicyclo[3,3,0]octyl, bicyclo[2,2,1]heptyl or bicyclo[2,2,2]octyl group, R 1 and R 3 are independently hydrogen, C 1-4 alkyl or phenyl-C 1-4 alkyl, and R 2 , R 4 and R 5 are independently hydrogen or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or diluent therefor.
Claim 15
Independent Claim
88 words
A method for prevention or treatment of hypertension in a mammal, which comprises administering to said mammal an effective antihypertensive amount of a compound of the formula: ##STR13## wherein A is a C 3-8 cycloalkyl, C 5-8 cycloalkenyl, cyclohexadienyl, phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, bicyclo[4,4,0]decyl, bicyclo[4,3,0]nonyl, bicyclo[3,3,0]octyl, bicyclo[2,2,1]heptyl or bicyclo[2,2,2]octyl group, R 1 and R 3 are independently hydrogen, C 1-4 alkyl or phenyl-C 1-4 alkyl, and R 2 , R 4 and R 5 are independently hydrogen or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof.
Claim 16
Independent Claim
88 words
A method for prevention or treatment of hypertension in a mammal, which comprises administering to said mammal an effective antihypertensive amount of a compound of the formula: ##STR13## wherein A is a C 3-8 cycloalkyl, C 5-8 cycloalkenyl, cyclohexadienyl, phenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, bicyclo[4,4,0]decyl, bicyclo[4,3,0]nonyl, bicyclo[3,3,0]octyl, bicyclo[2,2,1]heptyl or bicyclo[2,2,2]octyl group, R 1 and R 3 are independently hydrogen, C 1-4 alkyl or phenyl-C 1-4 alkyl, and R 2 , R 4 and R 5 are independently hydrogen or C 1-4 alkyl, or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4105776A
Cited
EP0007477A1
Cited
EP0012401A1
Cited
EP0018104A2
Cited
US4256761A
Cited
US4256761B1
Cited
EP0035868A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-18 | 1988-03-19 | 1988-09-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-18 | 1992-03-19 | 1992-09-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-18 | 1996-03-19 | 1996-09-18 | $7700.00 | Window Closed / Lapsed |